Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $167 | $131 | $196 | $242 |
| % Growth | 27.3% | -33.1% | -18.8% | – |
| Cost of Goods Sold | $11 | $35 | $53 | $62 |
| Gross Profit | $156 | $96 | $143 | $179 |
| % Margin | 93.4% | 73.3% | 73.1% | 74.3% |
| R&D Expenses | $21 | $25 | $36 | $32 |
| G&A Expenses | $79 | $53 | $70 | $47 |
| SG&A Expenses | $79 | $53 | $70 | $47 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $79 | $7 | $34 | -$3 |
| Operating Expenses | $179 | $84 | $140 | $76 |
| Operating Income | -$23 | $12 | $3 | $104 |
| % Margin | -13.5% | 9.1% | 1.5% | 43% |
| Other Income/Exp. Net | $25 | $52 | $33 | -$32 |
| Pre-Tax Income | $3 | $64 | $36 | $72 |
| Tax Expense | $7 | $10 | $41 | -$4 |
| Net Income | -$4 | $52 | -$33 | $57 |
| % Margin | -2.4% | 39.7% | -17% | 23.7% |
| EPS | -0.22 | 3.02 | -1.98 | 3.46 |
| % Growth | -107.3% | 252.5% | -157.2% | – |
| EPS Diluted | -0.22 | 2.94 | -1.98 | 3.34 |
| Weighted Avg Shares Out | 18 | 17 | 17 | 17 |
| Weighted Avg Shares Out Dil | 18 | 18 | 17 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $8 | $2 | $1 |
| Interest Expense | $3 | $1 | $2 | $20 |
| Depreciation & Amortization | $35 | $37 | $43 | $51 |
| EBITDA | $41 | $101 | $81 | $143 |
| % Margin | 24.4% | 76.8% | 41.4% | 59.1% |